Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000187563 | SCV000241157 | uncertain significance | not provided | 2020-02-27 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Labcorp Genetics |
RCV001085182 | SCV001005280 | likely benign | Cerebral creatine deficiency syndrome | 2024-11-04 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV000187563 | SCV001715486 | uncertain significance | not provided | 2019-05-06 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002433841 | SCV002750683 | uncertain significance | Inborn genetic diseases | 2017-06-12 | criteria provided, single submitter | clinical testing | The p.R100W variant (also known as c.298C>T), located in coding exon 2 of the GAMT gene, results from a C to T substitution at nucleotide position 298. The arginine at codon 100 is replaced by tryptophan, an amino acid with dissimilar properties. This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV001275205 | SCV004235111 | uncertain significance | Deficiency of guanidinoacetate methyltransferase | 2023-11-01 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001275205 | SCV001460084 | likely benign | Deficiency of guanidinoacetate methyltransferase | 2019-10-28 | no assertion criteria provided | clinical testing |